1998
DOI: 10.1093/jnci/90.23.1817
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer

Abstract: For PSA values of 0-3.9 ng/mL, the positive predictive value and sensitivity of DRE, tumor volume, and tumor grade were strongly dependent on PSA level. DRE has a poor performance in low PSA ranges.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
66
0
10

Year Published

2000
2000
2007
2007

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 296 publications
(82 citation statements)
references
References 26 publications
6
66
0
10
Order By: Relevance
“…The same conclusion of the high efficacy of PSA has been reached in two other large scale screening studies [66][67][68]. A similar conclusion has been reached by Hugosson et al [69] who wrote: "PSA seems to be excellent as a prescreening test to identify the population at risk and which needs further evaluation [70,71]".…”
Section: Combined Androgen Blockade In Advanced Diseasesupporting
confidence: 65%
“…The same conclusion of the high efficacy of PSA has been reached in two other large scale screening studies [66][67][68]. A similar conclusion has been reached by Hugosson et al [69] who wrote: "PSA seems to be excellent as a prescreening test to identify the population at risk and which needs further evaluation [70,71]".…”
Section: Combined Androgen Blockade In Advanced Diseasesupporting
confidence: 65%
“…8 Clinical examinations in several other conditions in the perineum, such as anorectal abscesses and fistulas, as well as urological diseases also have been compared with other investigations such as magnetic resonance imaging or ultrasound. [17][18][19] These data tell that a well-performed clinical examination can reach far but that you get some extra information from further investigations.…”
Section: Discussionmentioning
confidence: 99%
“…Le toucher rectal n'est pas utilisé seul car il est peu sensible, il est en effet anormal chez moins de 40 % des patients ayant un cancer (37 % dans [14], 39 % dans [15]). Dans les études de dépistage, il est utilisé en complément au dosage du PSA d'une façon variable dans les différents pays : systématiquement dans certains pays, et en fonction du niveau du PSA dans d'autres.…”
Section: La Maladie Doit Exister à Un Stade Latent Reconnaissableunclassified